R&D, Aova sign agreement
Will market feed ingredient technology
Biotech company R&D LifeSciences LLC signed an agreement with Aova Technologies Inc. to market its aPLA2 Technology micro feed ingredient. Under the deal, R&D will distribute the feed ingredient technology via global channels, the company said.
Aova’s egg antibody platform uses a patented technology to make feed additives containing enzyme-specific antibodies that mitigate gut inflammation to aid animal growth, efficiency and development. R&D said it will use the technology to introduce ReNuvigen gut inflammation reduction product. Aova is a Wisconsin-based agricultural biotech company.